CY1106223T1 - Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις - Google Patents

Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις

Info

Publication number
CY1106223T1
CY1106223T1 CY20061101554T CY061101554T CY1106223T1 CY 1106223 T1 CY1106223 T1 CY 1106223T1 CY 20061101554 T CY20061101554 T CY 20061101554T CY 061101554 T CY061101554 T CY 061101554T CY 1106223 T1 CY1106223 T1 CY 1106223T1
Authority
CY
Cyprus
Prior art keywords
methods
threonine
protein kinase
function
compounds
Prior art date
Application number
CY20061101554T
Other languages
English (en)
Inventor
Gerald Mcmahon
Bernhard Kutscher
Eckhard Gunther
Herald APP
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of CY1106223T1 publication Critical patent/CY1106223T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται εν μέρει σε μεθόδους διαμόρφωσης της λειτουργίας σερίνης/θρεονίνης πρωτεϊνών κινασών με βασισμένες σε 5-αζακινοξαλίνη ενώσεις. Οι μέθοδοι ενσωματώνουν κύτταρα τα οποία εκφράζουν μία σερίνης/θρεονίνης πρωτεΐνη κινάση, όπως RAF. Επιπλέον, η εφεύρεση περιγράφει μεθόδους πρόληψης και θεραπευτικής αντιμετώπισης ανώμαλων συνθηκών συγγενών με σερίνης/θρεονίνης πρωτεΐνη κινάση σε οργανισμούς με μία ένωση αναγνωρισμένη από την εφεύρεση, Περαιτέρω, η εφεύρεση αφορά ενώσεις 5-αζακινοξαλίνης και φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν αυτές τις ενώσεις.
CY20061101554T 1997-10-06 2006-10-30 Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις CY1106223T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6112397P 1997-10-06 1997-10-06
PCT/US1998/020910 WO1999017759A2 (en) 1997-10-06 1998-10-05 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds

Publications (1)

Publication Number Publication Date
CY1106223T1 true CY1106223T1 (el) 2011-06-08

Family

ID=22033733

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101554T CY1106223T1 (el) 1997-10-06 2006-10-30 Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις

Country Status (31)

Country Link
US (2) US6180631B1 (el)
EP (1) EP1028729B1 (el)
JP (1) JP2001518496A (el)
KR (1) KR100633270B1 (el)
CN (1) CN1169527C (el)
AR (1) AR013542A1 (el)
AT (1) ATE336250T1 (el)
AU (1) AU757585B2 (el)
BG (1) BG64969B1 (el)
BR (1) BR9814814A (el)
CA (1) CA2306257C (el)
CY (1) CY1106223T1 (el)
CZ (1) CZ298775B6 (el)
DE (1) DE69835612T2 (el)
DK (1) DK1028729T3 (el)
ES (1) ES2268791T3 (el)
HK (1) HK1031836A1 (el)
HU (1) HUP0100302A3 (el)
IL (2) IL135103A0 (el)
MX (1) MXPA03011007A (el)
NO (1) NO316598B1 (el)
NZ (1) NZ503431A (el)
PL (1) PL192039B1 (el)
PT (1) PT1028729E (el)
RU (1) RU2223753C2 (el)
SK (1) SK4722000A3 (el)
TR (2) TR200000906T2 (el)
TW (1) TWI245765B (el)
UA (1) UA71555C2 (el)
WO (1) WO1999017759A2 (el)
ZA (1) ZA988961B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE366108T1 (de) * 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
BRPI0410633A (pt) * 2003-05-23 2006-06-13 Zentaris Gmbh piridopirazinas e uso das mesmas como moduladores de cinase
DE102004022383A1 (de) * 2004-05-06 2005-12-01 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
CA2529090A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
KR101400905B1 (ko) * 2005-11-11 2014-05-29 아에테르나 젠타리스 게엠베하 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2010003308A1 (zh) * 2008-07-10 2010-01-14 卞化石 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN104903320B (zh) * 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
DK3174868T3 (da) 2014-08-01 2021-11-08 Nuevolution As Forbindelser, der er aktive mod bromodomæner
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
US20190256492A1 (en) * 2018-02-19 2019-08-22 Washington University Alpha-synuclein ligands

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001017A (en) * 1972-12-05 1977-01-04 Ciba-Geigy Ag Process for the photopolymerization of ethylenically unsaturated compounds
US4043819A (en) * 1974-06-11 1977-08-23 Ciba-Geigy Ag Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3804990A1 (de) * 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
FR2656606B1 (fr) * 1989-12-28 1993-06-25 Roussel Uclaf Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure.
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase

Also Published As

Publication number Publication date
IL135103A (en) 2007-06-17
MXPA03011007A (es) 2004-02-27
ES2268791T3 (es) 2007-03-16
WO1999017759A2 (en) 1999-04-15
PT1028729E (pt) 2006-12-29
AR013542A1 (es) 2000-12-27
HK1031836A1 (en) 2001-06-29
PL192039B1 (pl) 2006-08-31
CA2306257A1 (en) 1999-04-15
CA2306257C (en) 2007-09-25
ZA988961B (en) 1999-10-04
NO20001748D0 (no) 2000-04-05
SK4722000A3 (en) 2002-06-04
US6727252B1 (en) 2004-04-27
KR100633270B1 (ko) 2006-10-16
TR200000906T2 (tr) 2000-11-21
RU2223753C2 (ru) 2004-02-20
EP1028729A2 (en) 2000-08-23
DE69835612T2 (de) 2007-08-16
IL135103A0 (en) 2001-05-20
ATE336250T1 (de) 2006-09-15
HUP0100302A3 (en) 2006-03-28
EP1028729B1 (en) 2006-08-16
CN1274284A (zh) 2000-11-22
BG104392A (en) 2000-12-29
US6180631B1 (en) 2001-01-30
CN1169527C (zh) 2004-10-06
AU9514198A (en) 1999-04-27
CZ20001129A3 (cs) 2000-10-11
DK1028729T3 (da) 2006-12-11
JP2001518496A (ja) 2001-10-16
NO20001748L (no) 2000-04-05
PL339860A1 (en) 2001-01-15
TR200100385T2 (tr) 2002-06-21
AU757585B2 (en) 2003-02-27
HUP0100302A2 (hu) 2001-06-28
WO1999017759A3 (en) 2000-01-06
NO316598B1 (no) 2004-03-01
CZ298775B6 (cs) 2008-01-23
BG64969B1 (bg) 2006-11-30
NZ503431A (en) 2002-07-26
UA71555C2 (en) 2004-12-15
TWI245765B (en) 2005-12-21
KR20010030934A (ko) 2001-04-16
DE69835612D1 (de) 2006-09-28
BR9814814A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
CY1106223T1 (el) Μεθοδοι διαμορφωσης λειτουργιας σepινης/θρεονινης πρωτεϊνης κινασης με βασισμενες σε 5-αζακινοξαλινη ενωσεις
NO20001555D0 (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
EA199900620A1 (ru) Фталазиноны
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
TR200000782T2 (tr) Resorsinol türevleri.
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE26835T1 (de) Tris(piperidylaminotriazylamino) verbindungen, ihre herstellung und ihre verwendung als stabilisierungsmittel fuer polymere.
ATE490311T1 (de) Mutanten der alpha-amylase
CR6540A (es) Trifluorobutenos nematicidas
CY1108470T1 (el) Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna
ATE253063T1 (de) 5-ht1f-agonisten
ES2189121T3 (es) Mezcla de estabilizantes para materiales organicos.
ATE330963T1 (de) Amorphe feste modifikation von bis(2,4- dicumylphenyl) pentaerythritdiphosphit
NO994584D0 (no) Tetrahydropyridforbindelser
ATE223919T1 (de) Ionische flüssigkeiten, ihre herstellung und ihre verwendung
IT1295933B1 (it) 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
EA200000522A1 (ru) 5-htагонисты
SE9604582D0 (sv) Novel compounds
TR199700547A2 (xx) N-asetonilbenzamid fungisitler.
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
DE60210970D1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
PA8478901A1 (es) Isoquinolinas
DE59808166D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
GR930100340A (el) Μέ?οδος για την καταπολέμηση εντόμων.